Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | ICMT | O60725 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23695497 | 1.00 | ALOX5 (0.36) | ALOX5CES2CES1KEAP1ICMT | |
| SCHEMBL12261646 | 1.00 | ALOX5 (0.36) | ALOX5CES2CES1KEAP1ICMT | |
| SCHEMBL2830906 | 0.92 | SLC6A3 (0.38) | ALOX5ICMTSLC6A3TSHRMAPT | |
| SCHEMBL23695650 | 0.92 | SLC6A3 (0.38) | ALOX5CES2CES1KEAP1ICMT | |
| SCHEMBL12261588 | 0.90 | SLC6A3 (0.40) | SLC6A3TSHRIDO1MAPTNPC1 | |
| Hydrochloric Acid SCHEMBL17818958 | 0.89 | SLC6A3 (0.39) | ICMTSLC6A3TSHRIDO1MAPT | |
| SCHEMBL24017068 | 0.77 | ALOX5 (0.42) | ALOX5CES2CES1KEAP1SLC6A3 | |
| SCHEMBL24017067 | 0.77 | ALOX5 (0.42) | ALOX5CES2CES1KEAP1SLC6A3 | |
| SCHEMBL1309752 | 0.75 | HSD17B2 (0.46) | ALOX5CES2CES1KEAP1ICMT | |
| Hydrochloric Acid SCHEMBL30098237 | 0.75 | ALOX5 (0.41) | ALOX5CES2CES1KEAP1ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135729-A1 | COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | CHENGDU BIOBEL COMPANY LIMITED (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135729-A1 | COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | CHENGDU BIOBEL COMPANY LIMITED (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2021147123-A1 | COMPOUND HAVING ANTISPORULANT ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | 成都贝诺科成生物科技有限公司 | 2021-07-29 | — | — | WO | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| EP-2766352-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (UHN) (CA) | 2014-08-20 | — | — | EP | disclosed |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERISTY HEALTH NETWORKS (CA) | 2014-02-20 | — | — | US | disclosed |
| EP-1697354-B1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2013053051-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-18 | — | — | WO | disclosed |
| EP-1818325-A2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2007-08-15 | — | — | EP | disclosed |
| CN-1989097-A | Process for the preparation of a diastereomerically enriched compound | DSM IP ASSETS BV (NL) | 2007-06-27 | — | — | CN | disclosed |
| EP-1381590-B1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1778620-A1 | PROCESS FOR THE PREPARATION OF A DIASTEREOMERICALLY ENRICHED COMPOUND | DSMIP Assets B.V. (NL) | 2007-05-02 | — | — | EP | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006008171-A1 | PROCESS FOR THE PREPARATION OF A DIASTEREOMERICALLY ENRICHED COMPOUND | DSM IP ASSETS B.V. (NL) | 2006-01-26 | — | — | WO | disclosed |
| EP-0010401-B1 | NOVEL (1-SUBSTITUTED) CYCLOALKYLMETHYL-ISOTHIOCYANATES, A PROCESS FOR THEIR PREPARATION, COMPOSITIONS COMPRISING THEM, AND THEIR USE AS PESTICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-05-05 | — | — | EP | disclosed |
| US-4216217-A | FUNGICIDES, INSECTICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-08-05 | — | — | US | disclosed |
| EP-0010401-A2 | Novel (1-substituted) cycloalkylmethyl-isothiocyanates, a process for their preparation, compositions comprising them, and their use as pesticides | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | ALOX5 428/4885CES2 2560/4885CES1 2009/4885 |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | ALOX5 1795/4885CES2 4249/4885CES1 2066/4885 |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K7, MAP3K1, MAP3K20 | ALOX5 3119/4885CES2 2805/4885CES1 2219/4885 |
| US-20230135729-A1 | COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | CASP9, CLPP, CASP1 | ALOX5 1433/4885CES2 4260/4885CES1 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.